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1. Introduction
Urooncological diseases account about 40% of all oncological pathologies in men and more
than 10% in women. Renal cell carcinoma (RCC) accounts for about 4% of all adult malig‐
nancies and is the most lethal urological cancer. 60 920 new cases of RCC have been diag‐
nosed in the US in 2011 and 13 120 died of cancer [1]. The patient death rate from RCC has
decreased in the last 15 years due to the improvements in early diagnosis and surgical treat‐
ment of the disease [1]. However, it is estimated that 1/3 of the patients with localized cancer
will develop distant metastasis after radical treatment [2]. Therefore, early identification of
metastatic disease, timely and proper treatment is the main goal in the management of RCC.
The most common sites of metastases of RCC are: lymph nodes, lungs, liver, bones and
brain [3]. It is known that the disease can metastasize to almost every organ. Adrenal meta‐
stasis of RCC is relatively rare. It can be: synchronous or metachronous; ipsilateral, contrala‐
teral or bilateral; solitary or part of a massive metastatic spread. Malignant involvement of
the ipsilateral adrenal gland has been detected in up to 10% of the radical nephrectomy
specimens [4-8]. Contralateral adrenal metastasis however, is uncommon. In the autopsy
study of more than 400 patients who had undergone nephrectomy for RCC, the solitary con‐
tralateral adrenal metastasis has been detected in only 2.5% of cases [9].
The predisposing factors for the disease spread and the optimal treatment of this rare com‐
plication are not fully understood. It is well-known that some patients with isolated meta‐
stasis may benefit from surgical treatment. However, the optimal diagnosis and treatment of
the contralateral adrenal metastasis from RCC is not yet well defined. The available infor‐
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mation on the outcomes of various treatment options of this complication is limited and
mainly based on a sporadic case reports.
In this chapter we analyze all 65 cases of the contralateral adrenal metastases of RCC report‐
ed in the literature [10-32]. Our single center experience of treatment of four patients with
this complication is also presented. The chapter describes the current view on the pathogen‐
esis, diagnosis and management as well as the surgical, pathological and oncological results
of treatment of this rare complication.
The natural course of the RCC is unpredictable. The disease can metastasize to any organ,
any time even many years after the operation [33, 10]. Metastasis from the RCC has been
discovered as late as 23 and 31 years after radical nephrectomy [33, 34]. The contralateral
adrenal metastasis from RCC is extremely rare. Only 69 cases (including our series) can be
found in the literature.
The exact reasons of late development of the adrenal metastasis are not completely clear.
One of the possible explanations could be that some metastases, especially those of low
grade, can grow very slowly. Besides, improper patient follow-up i.e. not using a routine
imaging studies for a long time might explain the late detection of some metastasis.
Adrenal metastasis from renal tumors is more common to the ipsilateral adrenal gland. The
pathological mechanisms for secondary involvement of the contralateral adrenal gland are
unknown. It is thought that the disease spreads via hematogenous route as in case of other
organ metastases. However, the autopsy studies illustrate that contralateral adrenal metasta‐
ses occur far more often than should be expected on the basis of organ size [18]. Explanation
of this fact can be a rich blood supply of the adrenal gland and its high blood volume-to-unit
weight ratio [35]. It has been speculated that as far as the contralateral adrenal metastasis
has occurred the adrenal gland will have a higher affinity to the RCC cells than other organ
tissues [4]. In another words, if the tumor cell reaches the adrenal gland the later acts as a
fertile soil and stimulates raise of these cells [18]. In consistent with this theory some studies
are showing that the adrenal metastases from the contralateral primary RCC grew to a con‐
siderable size without metastasing to other organs. Utsumi T, et al. describe a huge
(85X90mm) contralateral adrenal metastasis that had invaded the kidney, renal vein, and in‐
ferior vena cava but without any involevement of other organs [32].
The risk-factors for development of the adrenal metastasis have been analyzed by some of
the studies. Importance of the several clinicopathological features of the primary RCC has
been reported. These are: tumor size, left sided tumor, advanced T-stage, and upper-pole tu‐
mor location [4, 36].
Adrenal metastases are usually anatomically and functionally silent and patients rarely have
symptoms or signs of adrenal insufficiency. Therefore, abdominal imaging is not routinely
used for follow-up and the isolated contralateral adrenal metastasis from RCC is rarely diag‐
nosed during a lifetime. This should contribute to the late disease diagnosis, treatment and
the worse prognosis.
Due to rare occurrence, the optimal diagnostic approach to a solitary contralateral adrenal
metastasis in the patients with a history of RCC is controversial. It can be different from the
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adrenal incidentalomas. Imaging studies usually cannot verify with certainty the adrenal
masses detected in the patients previously operated due to the RCC. It is always difficult to
determine whether the mass is: primary adrenal tumor (carcinoma), benign tumor (i.e. an
adrenal cortical adenoma) or metastasis. Preoperative diagnosis of synchronous adrenal
metastases is relatively easy and is mainly based on radiological findings from abdominal
CT and/or MRI. The finding of solitary adrenal mass without elevated serum adrenocortical
hormones is strongly suggestive of a metastatic lesion. Metastatic adrenal tumors are usual‐
ly well-vascularized as compared with the adrenal cortical adenoma or primary adrenal car‐
cinoma. The later ones are more hypovascular [30].
CT is a highly specific in diagnosing adrenal metastases. In 82% of cases reported in the lit‐
erature, contralateral adrenal metastases have been diagnosed by abdominal CT. Antonelli
et al. reviewed clinical records of 1179 surgically treated RCC patients and found that 15 had
suspicious findings in the contralateral adrenal glands on CT. Only one of the 15 surgically
removed adrenals was found to be free of tumor. The authors reported positive and nega‐
tive predictive value of CT as 73% and 96% in detecting the adrenal metastases. Remarkably,
the positive predictive value of CT in diagnosing the contralateral adrenal metastases was
higher [32]. It should be noted that accuracy of CT for distinguishing between benign and
malignant contralateral adrenal nodules has improved recently using CT protocols to evalu‐
ate the wash-out of contrast media [37].
We’ve analyzed the records of six hundred twenty nine patients who underwent radical
nephrectomy for RCC in our center between 1991 and 2005. The mean patient age was
55.7±11.3 years (range: 12-85 years). 422 (67.2%) were man and 207 (32.8%) were women.
The mean follow-up is 60.5±1.7 months (range: 1-187 months). The pathological stage distri‐
bution of the tumor was the following: T1 –132 (21%); T2 – 229 (36.4%); T3 – 256 (40.7%); T4 -
12 (1.9%) patients. 123 (19.4%) cancers were G1, 277 (44.1%) - G2 and 229 (36.5 %) - G3.
Morphological evaluation revealed clear cell RCC in 475 patients (75.6%). 38 (6.1%) patients
had lymph node and 28 (4.5%) patient had distant metastases at the time of surgery. 170
(27%) tumors were discovered incidentally, 332 (52.8%) were locally symptomatic and 127
patients (20.2%) had a systemic disease symptoms.
Four cases  (0.6%) of  isolated contralateral  adrenal  metastasis  have been diagnosed with
the mean follow-up of 83.3 months (range: 23-196 months). In accordance with the exist‐
ing data from the literature all  four metastases have been detected by CT. The metasta‐
ses  have  been  diagnosed  synchronously  in  one  (0.1%)  and  metachronously  in  three
(0.5%) cases. Mean age of the patients was 56 years (range: 47-68 years). All the patients
underwent adrenalectomy through flank incision above the 11th rib. No patient received
any form of adjuvant systemic therapy.
All  four  patients  had  undergone  contralateral  radical  nephrectomy  due  to  the  conven‐
tional RCC. All removed kidneys and adrenal were sent to the department of pathology
of the same institution (National Centre of Urology). The same team of personnel accord‐
ing to the single protocol has technically processed all the tissue specimens. The surgical
margins  of  the  primary  nephrectomy  specimens  were  recorded  as  positive  or  negative
based on the gross and microscopic examination of the specimen. The adrenal gland was
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examined macroscopically,  sliced in 2- to 3-mm cross sections and processed for further
microscopical evaluation.
Morphological parameters assessed for both the primary and metastatic tumors included:
stage, histological subtype, nuclear grade and presence of tumor necrosis. The stained slides
from all tumor and metastases specimens were reviewed by urological pathologist, as de‐
scribed previously [38]. Shortly, the resected kidneys and adrenals were evaluated macro‐
scopically. The maximal tumor size was measured and 1.5 x 2cm tissue samples were taken
for further assessment. Specimens were fixed, stained and evaluated by the same patholo‐
gist according to conventional technique. The tumors were staged according to the AJCC
classification system and graded according to Fuhrman’s grading system.
The mean (range) diameter of the primary renal tumor was 76±27.9 mm (12-200 mm) and
the mean diameter of the adrenal metastases was 6.4 cm (range: 3–9 cm). The clinical and
pathological features of the primary tumors for the 4 patients with contralateral adrenal
metastasis are summarized in Table 1. The pathological stage of the adrenal metastasis was
pT2N0 and pT3aN0 in two patients each. Grade 2 tumor was detected in one and grade 3 in
three cases.
N Age Sex Time from surgery to
metastasis (months)
Side of
metastasis
Stage Grade Follow-up Patient
status
1 47 M 18 Right T3a 3 31 Dead
2 58 M 64 Right T2 3 78 Dead
3 57 F 24 Right T3a 3 165 Alive
4 73 F 156 Left T2 2 180 Alive
Table 1. The characteristics of four patients with contralateral adrenal metastasis.
One patient had synchronous contralateral adrenal metastasis. The mean time from the pri‐
mary nephrectomy to contralateral adrenal metastasis for the remaining three patients was
65.5 months (range: 18–156 months).
Adrenal biopsy can be advocated in some cases. The biopsies of RCC has been lately aban‐
doned due to the following reasons: a) the predictive value of the imaging findings usually
is so high that a negative biopsy result would not alter the management strategy; b) 10-20%
of biopsies are reported to be non-conclusive; c) high risk of complications associated with
the biopsy [39].
Early diagnosis and treatment of metachronous adrenal metastases is more challenging as it
can occur many years after the operation. This depends on the mode of follow-up, diagnos‐
tic techniques used and early referral of the patient to the specialized clinic. In our study the
adrenal metastases have been detected at the mean 65.5 months after radical nephrectomy.
A wide variability of latency in diagnosis of the metastases has been reported by others as
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well. These data indicate on the necessity of prolonged surveillance, especially in the high
risk patients i.e. with advanced disease stage [31, 40].
The survival of patients with RCC mainly depends on the disease spread. Widely metastatic
RCC usually have a poor prognosis with a mean survival of 11 months. On the contrary, in
the patients with solitary or limited metastases resection of the metastases can be associated
with prolonged survival (30% survival at 5 years) [39]. Reports of successful outcomes and
subsequent long-term survival after treatment of solitary metastases of the RCC justify an
aggressive surgical approach [10]. In light of the existing data, complete resection of the pri‐
mary renal and metastatic adrenal tumors should be the main clinical strategy in these pa‐
tients. Thus, in case of adrenal metastases whether it is synchronous or metachronous,
ipsilateral or contralateral, complete removal of adrenal gland is a treatment of choice pro‐
viding the best results [30].
Adrenalectomy can be performed either laparoscopically, retroperitoneoscopically or by ro‐
botic surgery, decreasing the surgery-associated morbidity and hospital stay [20]. We’ve
performed open adrenalectomy in all our patients. The operation was uneventful in all of
them. The mean operation time was 136 minutes (range: 110-160 minutes). All metastases
were clear cell RCC tumors. The mean blood loss was 175 ml (range: 50-350 ml). The mean
hospital stay was 6 days (range: 4-10 days). No patient had positive surgical margins from
the adrenalectomy. There are no data on the efficacy of any form of systemic therapy in the
treatment of solitary adrenal metastasis.
The available data on the outcome of the surgical treatment of the contralateral adrenal
metastases form RCC are limited and biased. Table 2 summarizes the data of 65 patients
with contralateral adrenal metastasis reported in the literature [10-32]. Characteristics of the
patients (age, sex), interval between the primary surgery and diagnosis of the adrenal meta‐
stasis, and clinical outcome of the patients are described.
These are mainly the case reports of 1-2 cases. The biggest series of 11 cases has been report‐
ed by Lau WK, et al. from the Mayo clinic in 2003. In this report 82% of the metastases were
metachronous, diagnosed at the mean 4.2 years (0-9.2 years) after the nephrectomy. Other
relatively big series of 7 and 8 patients have been reported by Plawner J. and Antonelli A. in
1991 and 2006, respectively.
57% of all metastases reported up to now have been detected synchronously and 43% were
discovered metachronously at the mean 2.8 years (0-23 years) after the radical nephrectomy.
58% of the patients were male and 42% were female. The majority (62%) of metastases de‐
veloped on the left side. Abdominal CT was the preferred method of diagnosis in the vast
majority of cases (82%) followed-up by arteriography (6%) and IVP (2%).
At the mean follow-up of 6.8 years (0.3-14.3 years) 29 patients (55%) were alive without evi‐
dence of disease and 18 patients (34%) were dead of disease. Surgical removal of the adrenal
gland was the only treatment used in these patients. None of the patients received any form
of adjuvant systemic therapy.
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Reference N of
cases
Chronicity Age
(years)
Sex Time from
nephrectomy
(years)
Side Method of
diagnosis
Follow-up
(years)
Patient
status
10 1 s NS NS 0 NS NS 0.6 NED
12 2 s, s 58, 80 M, M 0, 0 L, R NS, IVP 1.5, 1.8 DOD, NED
13 2 s, s 54, 57 M, F 0, 0 R, L Art, Art 3, NS NED, NS
14 2 s, s 54, 55 F, F 0, 0 L, R CT, Art 1.7, 2 NED, NED
15 2 m, m 57, 46 M, F 0.5, 1 R, L CT, CT 2.2, 1.8 NED, NED
16 2 s, m 67, 68 M, M 0, 15 R, L CT, CT 0.4, 1 NED, NED
17 2 m, m 46, 69 M, M 2, 4 L, R CT, CT 2.5, 4 DOD, NED
18 1 s 60 F 0 R CT 0.8 NED
19 7 s, s, m, s, m, m, s 63, 55, 55,
48, 70, 57,
71
All M 0, 0, 3.6, 0, 7, 6.8, 0 L, R/L, R,
R, L, L, L
NS 14.3, 4.8, 0.8,
0.6, 5, 2.7,
6.7
DOD, DOD,
DOD, DOD,
NED, NED
DOD
20 2 m, m 49, 82 M, M 5, 5 R, R CT, CT 0.3, 1.3 NED, NED
21 5 All m 47, 59, 69,
57, 72
F, F, F, M,
M
1.5, 1.5, 5.3, 2, 17.8 NS All CT 2, 0.7, 3.7,
5.3, 3.5
DOD, DOD,
NED, NED,
NED
22 2 s, m 63, 64 M, F 0, 4 L, L CT, CT 1, 5 NED, NED
23 1 s 52 M 0 R CT 7 NED
24 1 m 52 M 0.8 R CT 7.3 NED
25 1 m NS M 23 NS NS 1 NED
26 1 s NS NS 0 NS CT NS NS
27 4 s, s, s, m All NS All NS 0, 0, 0, NS NS NS 9, 5.4, NS, NS DOD, AWD,
NS, NS
28 1 m 63 M 22 L CT 5.6 NED
29 1 m 50 F 7.5 R CT 2.5 NED
30 11 m, m, m, m, s, m,
m, m, s, m, m
69, 43, 49,
64,54, 54,
67, 53,68,
70, 79,
M, M, M,
M, M, M,
F, M, M,
F, M
6.1, 7.3, 9.2, 9.1, 0, 1,
6.7, 5.8, 0, 0.8, 1
L, L, R, R,
R, L, L, L,
R, R, L
All CT 1.7, 0.9, 1.9,
0.5, 6.6, 9.9,
3.4, 3.7, 9.2,
4.4, 1.2
DU, DOD,
DOD, NED,
DOD, DOD,
DOC, DOD,
NED, DOD,
DOD,
31 8 s-6, m-2 NS NS NS NS All CT NS NS
32 1 s 64 M 0 R CT 0.5 NED
Art, arteriography; AWD, alive with disease; DOC, dead of other causes; DOD, dead of disease; DU, dead of unknown
cause; F, female; IVP, intravenous pyelogram; L, left; m, metachronous; M, male; NED, no evidence of disease; NS, not
stated; R, right; s, synchronous.
Table 2. Characteristics of the patients treated for the contralateral adrenal metastasis published in the literature.
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From our series of four patients, two are alive 141 and 24 months after adrenalectomy with‐
out signs of disease recurrence. Two patients died from multiple metastases 13 and 14
months after adrenalectomy, including the patient with synchronous contralateral adrenal
metastasis.
For the entire group of patients, the 5 and 10 years disease–specific survival rates were 61.5
% and 25.6%, respectively. The 5-year overall survival for metastatic (N+ and M+) disease
was significantly worse as compared with the non-metastatic disease (6.25% and 72.8%, re‐
spectively) (p=0.0001).
There was no statistically significant difference when the survival of patients with solita‐
ry  adrenal  lesions  was  compared  to  that  of  the  patients  with  organ–confined  primary
RCC.  Furthermore,  no  differences  in  survival  have  been  detected  between  the  patients
with  synchronous  or  metachronous  adrenal  metastasis  (p=0.346  for  overall  survival;
p=0.256 for disease-specific survival). With multivariate statistical analysis the presence of
solitary  adrenal  metastases  was  not  predictive  of  the  clinical  prognosis  of  the  patients
following adrenalectomy.
The biggest number of the patients with contralateral adrenal metastasis from RCC reported
in the literature is 11 [30]. This number is small for making the strong conclusions. Majority
of the available studies indicate that the surgical treatment of the complication is worth‐
while in selected patients [22, 23]. One study demonstrated that patients in whom RCC
metastases (both synchronous and metachronous) were clinically confined to the adrenal
gland had statistically better survival rates than those with diffuse metastasis [31]. In about
one-third of the RCC patients with isolated adrenal metastasis, surgical resection of the
metastasis led to an apparently curative outcome [32]. The longest disease-free survival after
removing a contralateral adrenal metastases form RCC is 12.1 years [41], and the longest
overall survival is 14.3 years [20]. In accordance with the literature, we didn’t find statistical‐
ly significant survival difference between the patients with localized RCC and solitary con‐
tralateral adrenal metastasis. Furthermore, with multivariate statistical analysis the presence
of solitary adrenal metastases was not predictive of the clinical prognosis of the patients fol‐
lowing adrenalectomy.
The exact reason why do these patients survive longer remains unclear. The several possible
explanations exist. It has been speculated that this is a localized disease and that complete
removal of the tumor improves prognosis. Another explanation is that the patient’s immune
system can probably inhibit microscopic disease after tumor debulking. Finally, it has been
postulated that this may be a naturally selected group of patients with slow-growing cancer
which is not very aggressive and does not metastasize readily [19].
2. Conclusion
In conclusion, the solitary contralateral adrenal metastasis from RCC is an extremely rare
clinical complication that can occur very late after the radical nephrectomy. The increased
Surgical and Oncological Results of Treatment of Metastases of Renal Cell Carcinoma to the Contralateral Adrenal
Gland
http://dx.doi.org/10.5772/53745
139
use of radiological diagnostic tests like: ultrasound, CT and/or MRI has led to more efficient
detection of these lesions. Aggressive surgery remains the treatment of choice in these cases
improving prognosis in some of the patients. There is no doubt that the existing data are
limited and we need more studies to define the optimal management strategy in the patients
with contralateral adrenal metastasis from RCC.
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